-+ 0.00%
-+ 0.00%
-+ 0.00%
12 Health Care Stocks Moving In Monday's After-Market Session
Share
Listen to the news

Gainers

  • Vicore Pharma Holding (NASDAQ:VCRE) stock rose 149.8% to $42.47 during Monday's after-market session.
  • Crinetics Pharmaceuticals (NASDAQ:CRNX) stock moved upwards by 99.85% to $84.0. The company's market cap stands at $4.4 billion.
  • Aligos Therapeutics (NASDAQ:ALGS) shares moved upwards by 19.65% to $7.0. The market value of their outstanding shares is at $34.5 million.
  • Zhengye Biotechnology (NASDAQ:ZYBT) shares rose 9.98% to $0.72. The company's market cap stands at $30.6 million.
  • Aktis Oncology (NASDAQ:AKTS) shares moved upwards by 6.15% to $28.2. The market value of their outstanding shares is at $1.7 billion.
  • Bluejay Diagnostics (NASDAQ:BJDX) stock rose 6.03% to $1.23. The market value of their outstanding shares is at $1.1 million.

Losers

  • Celularity (NASDAQ:CELU) stock declined by 11.3% to $0.71 during Monday's after-market session. The company's market cap stands at $17.6 million.
  • RxSight (NASDAQ:RXST) stock fell 10.66% to $5.02. The market value of their outstanding shares is at $232.2 million.
  • China Pharma Holding (AMEX:CPHI) stock decreased by 10.43% to $0.61. The company's market cap stands at $29.0 million.
  • MaxCyte (NASDAQ:MXCT) stock fell 9.45% to $1.15. The market value of their outstanding shares is at $130.1 million.
  • Jasper Therapeutics (NASDAQ:JSPR) shares decreased by 8.82% to $0.42. The company's market cap stands at $11.9 million.
  • Innovative Eyewear (NASDAQ:LUCY) stock decreased by 7.26% to $1.15. The company's market cap stands at $4.8 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending